Fig. 3.

Effects on splenocyte phenotype in vivo. B16 cells were implanted on day 1. Beginning on day 10, mice were treated with decitabine (DAC), IL-2, and/or ODN1826 (ODN) for 2 weeks. A group of mice was not treated (NT). Splenocytes were collected on day 24. a CD3⁺, CD4⁺, CD8⁺ T cells, NK1.1⁺ NK, and B220⁺ B cells were determined by flow cytometry. b CD4⁺CD25⁺FoxP3⁺ Treg cells and CD11b⁺Gr1⁺ MDSC were determined by flow cytometry. Data represent mean ± SD, n = 4 mice per group. *P < 0.05 compared to without DAC